Branded generics

The US treadmill hides two things. One makes Indian pharma a surprisingly good business, and the other stops you mis-labelling a different animal.

Why do branded generics earn higher margins in India?

(A) India branded generics: why the same molecule earns 25%+ EBITDA at home. This is the trick that funds the whole US fight. In the United States a generic is a commodity. The pharmacist substitutes the cheapest bioequivalent at the counter, and price is the only variable. In India there's no automatic substitution. The doctor prescribes a brand, one specific company's version of, say, metformin or atorvastatin. The chemist dispenses that brand, and the prescription habit stays sticky for years. So a molecule that's off-patent everywhere on earth becomes, in India, a branded franchise with the economics of a consumer staple:

• Pricing power. The brand competes instead of the molecule, so gross margins run 60–70% and EBITDA margins 25–30%+, against the US commodity's mid-teens.
• Stickiness. Chronic therapies (diabetes, cardiac, CNS, respiratory) are drugs taken for life. They renew month after month, and the revenue compounds like a subscription.
• A field-force moat. Thousands of medical representatives call on doctors to build brand recall and relationships that a new entrant can't replicate cheaply. The cornered resource here is the doctor relationship plus the brand, defended by distribution reach.

What limits branded generics, and how should you value them?

There are limits. The NPPA (National Pharmaceutical Pricing Authority) caps the prices of essential drugs under the DPCO (Drug Price Control Order), using the NLEM (National List of Essential Medicines). Roughly a sixth to a fifth of the market is under a ceiling, and the list keeps expanding. Competition is relentless too, with tens of thousands of brands, and the government pushes generic-generics through Jan Aushadhi. For valuation, though, keep one thing in view. An "India branded generics" rupee of profit and a "US generics" rupee of profit are different rupees. One is a sticky, high-return annuity that deserves a consumer-staples multiple, something like a P/E in the high 20s–30s. The other is a commodity treadmill worth a low-teens multiple. A company that reports both as one blended EBITDA is inviting you to mis-value it. Segment it, and prize the chronic branded mix most. Chronic therapy compounds, while acute therapy (one-off infections) doesn't.

How does innovator pharma differ from generics?

(B) The innovator contrast: don't bring a generics playbook to a patent fight. Not all pharma is generics. Innovator (originator) pharma plays the opposite game. It spends 15–25% of sales on R&D to invent new molecules and wraps them in patents (20 years from filing, ~10–13 years of effective post-launch life). Then it earns monopoly prices until the cliff. Carry three ideas from it and no more. This is a hand-off to the Phase 3 special-situations material, built on Damodaran's pharma work, and it isn't a full playbook:

1. The patent cliff. When a blockbuster loses exclusivity, generics enter and its sales fall 80–90% in one to two years. Atorvastatin/Lipitor and clopidogrel/Plavix went this way, and adalimumab/Humira is the modern biosimilar-paced version. So an innovator's trailing earnings can be a trap, cheap on today's P/E with the cliff dead ahead.
2. Pipeline valuation. You value an innovator on its pipeline instead of its trailing profit. The risk-adjusted NPV of each candidate = peak sales × probability of success × margin, discounted. Success probabilities are brutal and depend on the stage: roughly Phase I ~10%, Phase II ~30%, Phase III ~60%, filed ~85–90% (approximate industry base rates). The value is in molecules that earn nothing today.
3. So the multiple lies both ways. A "cheap" innovator may be a value trap (cliff) or a bargain (undervalued pipeline), and a "dear" one may be fair (rich pipeline). You can't read it off a trailing multiple, and that's the whole reason the generics playbook and the innovator playbook must never be confused. Most Indian pharma is generics plus branded generics. A few franchises, such as Sun's specialty molecules and the biosimilar builders, are climbing toward innovation. In the US the split is stark, with pure innovators (Pfizer, Merck, Lilly) on one side and the generics pure-plays on the other.

What does Teva show about US generics?

For a US cautionary anchor, look at Teva. Set against the Indian majors' branded-generics ballast, Teva is the object lesson in a US generics business without enough of that ballast (illustrative). The world's largest generics company doubled down on US commodity generics, buying Actavis Generics for ~$40bn in 2016, at the top. It did so just as the three buying consortia consolidated and erosion spiked to low double digits. At the same time, US state attorneys-general launched a price-fixing probe and opioid litigation piled on. The equity fell on the order of ~90% from its peak and spent years deleveraging.

In the language of this playbook, the diagnosis is US revenue eroding, too little complex/branded pipeline behind it, and a balance sheet that removed the margin for error. That's the sector's red flag, lived at the largest scale in the industry. It's the mirror image of the Sun/Cipla-style Indian model, where a fat, sticky India brand funds a selective, complexity-tilted US push. That model has compounded where the pure US commodity model hasn't.